MULLERIAN-INHIBITING SUBSTANCE IN FOLLICULAR-FLUID AND SERUM - A COMPARISON OF PATIENTS WITH TUBAL FACTOR INFERTILITY, POLYCYSTIC-OVARY-SYNDROME, AND ENDOMETRIOSIS

Citation
Me. Fallat et al., MULLERIAN-INHIBITING SUBSTANCE IN FOLLICULAR-FLUID AND SERUM - A COMPARISON OF PATIENTS WITH TUBAL FACTOR INFERTILITY, POLYCYSTIC-OVARY-SYNDROME, AND ENDOMETRIOSIS, Fertility and sterility, 67(5), 1997, pp. 962-965
Citations number
6
Categorie Soggetti
Obsetric & Gynecology
Journal title
ISSN journal
00150282
Volume
67
Issue
5
Year of publication
1997
Pages
962 - 965
Database
ISI
SICI code
0015-0282(1997)67:5<962:MSIFAS>2.0.ZU;2-B
Abstract
Objective: To determine Mullerian inhibiting substance (MIS) levels in follicular fluid (FF) and sera of IVF patients. Design: Prospective s tudy. Setting: Fertility center. Patient(s): Sixty-six patients: 20 wi th tubal factor infertility, 17 with polycystic ovary syndrome (PCOS), and 29 with endometriosis. Intervention(s): All patients underwent ov arian stimulation with hMG and/or FSH, as well as oocyte retrieval for IVF. Main Outcome Measure(s): Follicular fluid and serum MIS levels a nd oocyte fertilization rates. Result(s): Levels of MIS in FF and sera of PCOS patients were significantly higher than those in tubal factor patients: 7.01 +/- 1.52 versus 1.65 +/- 0.23 ng/mL (mean +/- SE) and 2.97 +/-0.52 versus 0.92 +/- 0.19 ng/mL, respectively. In endometriosi s patients, follicular fluid and serum MIS levels were not significant ly different from those in tubal factor patients. In PCOS patients, th e percentage of immature oocytes retrieved (17.9% +/- 5.0%) was signif icantly higher compared with tubal factor (1.5% +/- 1.0%) and endometr iosis (9.2% +/- 2.3%) patients. The percentage of oocytes fertilized w as significantly lower in PCOS patients (30.2% +/- 5.3%) compared with tubal factor (62.2% +/- 5.5%) and endometriosis (37.5% +/- 5.7%) pati ents. Conclusion(s): Women with PCOS had higher serum and follicular f luid MIS levels, a higher percentage of immature oocytes, and lower fe rtilization rates than women with endometriosis or pelvic adhesions. ( C) 1997 by American Society for Reproductive Medicine.